Adaptive pathways should be 'exception rather than rule'
This article was originally published in SRA
Make adaptive pathways for medicines evaluation the exception rather than the rule and focus instead on therapeutic advance. A number of health groups have joined forces to send precisely that message to the European Medicines Agency.
Register for our free email digests: